Fallopian tube cancer

Fallopian tube cancer is a rare, aggressive gynecologic malignancy. Recent genetic and immunohistochemical studies strongly suggest that high-grade serous adenocarcinoma (SAC) involving the ovary likely arises from distal fallopian tube epithelium, indicating that some ovarian cancers develop in the fallopian tube and are then spread to the ovary. Fallopian tube cancers are similar to ovarian cancer with respect to the proportion of tumors with abnormal expression of c-erbB-2 and p53. It has been proposed that the p53 signature is the earliest step in the pathogenesis of fallopian tube cancer. In this model, tubal epithelium on the fimbria experiences genotoxic damage and, as a result, the secretory cell exhibits over-accumulation of p53 protein (p53 signature). There is also some evidence that BRCA-1 and BRCA-2 mutations and c-myc have a major role in tumorgenesis.

Cancer

BRCA1 (mutation) [HSA:672] [KO:K10605]
BRCA2 (mutation) [HSA:675] [KO:K08775]
TP53 (overexpression) [HSA:7157] [KO:K04451]
ERBB2 (overexpression) [HSA:2064] [KO:K05083]
c-myc (overexpression) [HSA:4609] [KO:K04377]

Bevacizumab [DR:D06409]
Niraparib [DR:D10140]

PMID:25286779 (marker)

Horng HC, Teng SW, Huang BS, Sun HD, Yen MS, Wang PH, Tsui KH, Wen KC, Chen YJ, Chuang CM, Chao HT, Chang WH

Primary fallopian tube cancer: domestic data and up-to-date review.

Taiwan J Obstet Gynecol 53:287-92 (2014)
DOI:10.1016/j.tjog.2014.07.003

PMID:23622731 (description, gene, marker, drug)

Kalampokas E, Kalampokas T, Tourountous I

Primary fallopian tube carcinoma.

Eur J Obstet Gynecol Reprod Biol 169:155-61 (2013)
DOI:10.1016/j.ejogrb.2013.03.023

PMID:23937438

Nik NN, Vang R, Shih IeM, Kurman RJ

Origin and pathogenesis of pelvic (ovarian, tubal, and primary peritoneal) serous carcinoma.

Annu Rev Pathol 9:27-45 (2014)
DOI:10.1146/annurev-pathol-020712-163949

PMID:21922146

Haruta S, Furukawa N, Yoshizawa Y, Tsunemi T, Nagai A, Kawaguchi R, Tanase Y, Yoshida S, Kobayashi H

Molecular genetics and epidemiology of epithelial ovarian cancer (Review).

Oncol Rep 26:1347-56 (2011)
DOI:10.3892/or.2011.1456

PMID:24511245 (gene, drug)

Sama AR, Schilder RJ

Refractory fallopian tube carcinoma - current perspectives in pathogenesis and management.

Int J Womens Health 6:149-57 (2014)
DOI:10.2147/IJWH.S40889

PMID:7773939

Lacy MQ, Hartmann LC, Keeney GL, Cha SC, Wieand HS, Podratz KC, Roche PC

c-erbB-2 and p53 expression in fallopian tube carcinoma.

Cancer 75:2891-6 (1995)
DOI:10.1002/1097-0142(19950615)75:12<2891::AID-CNCR2820751216>3.0.CO;2-B

PMID:23240669

Vang R, Shih IeM, Kurman RJ

Fallopian tube precursors of ovarian low- and high-grade serous neoplasms.

Histopathology 62:44-58 (2013)
DOI:10.1111/his.12046

PMID:25315029 (drug)

Keating GM

Bevacizumab: a review of its use in advanced cancer.

Drugs 74:1891-925 (2014)
DOI:10.1007/s40265-014-0302-9